Pluri Inc. (NASDAQ:PLUR) Short Interest Update

Pluri Inc. (NASDAQ:PLUR) was the target of a significant growth in short interest during the month of December. As of December 31st, there was short interest totaling 14,548 shares, a growth of 59.8% from the December 15th total of 9,104 shares. Based on an average daily trading volume, of 42,290 shares, the short-interest ratio is presently 0.3 days. Approximately 0.2% of the shares of the company are sold short. Approximately 0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 42,290 shares, the short-interest ratio is presently 0.3 days.

Pluri Stock Up 5.6%

Shares of NASDAQ:PLUR opened at $3.22 on Friday. Pluri has a fifty-two week low of $2.82 and a fifty-two week high of $7.13. The firm’s 50-day simple moving average is $3.37 and its 200-day simple moving average is $4.26. The company has a market cap of $32.14 million, a price-to-earnings ratio of -0.68 and a beta of 0.66.

Pluri (NASDAQ:PLUR) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.65) EPS for the quarter. The company had revenue of $0.32 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pluri stock. Jane Street Group LLC bought a new position in shares of Pluri Inc. (NASDAQ:PLUR) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 10,928 shares of the company’s stock, valued at approximately $47,000. Jane Street Group LLC owned approximately 0.14% of Pluri as of its most recent filing with the Securities and Exchange Commission (SEC). 16.59% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Pluri in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $12.00.

About Pluri

Pluri (NASDAQ:PLUR) is a clinical-stage biotechnology company focused on the development and manufacturing of placental-derived cell therapy products. The company’s proprietary three-dimensional microcarrier expansion platform enables large-scale, off-the-shelf production of PLX (placental expanded) cells, which are being investigated for a range of acute and chronic conditions. Pluri’s approach seeks to combine the regenerative and immunomodulatory properties of stromal cells with a scalable manufacturing process that does not require patient-specific cell harvesting.

Pluri advances its pipeline through internally funded research programs and strategic collaborations with academic institutions and government agencies.